Commercial Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch BioPharma DiveA strong performance from Mounjaro overseas boosted Lilly s results, and the company raised its guidance for the year for both profit and revenue.Read full story pharminent April 30, 2026 (Last updated: May 1, 2026) BioPharma Dive A strong performance from Mounjaro overseas boosted Lilly s results, and the company raised its guidance for the year for both profit and revenue. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly clocks 56% revenue increase in Q1 but declining prices stunt growthNext: UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy Related Stories Commercial Lilly UK recruits ex-England cricketer as obesity champion pharminent May 15, 2026 Commercial A year after Vertex’s big launch, pain drug research faces a pivotal moment pharminent May 12, 2026 Commercial Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls pharminent May 11, 2026
